Soluble ACE2 as a Risk or Prognostic Factor in COVID-19 Patients: A Cross-sectional Study
Open Access
- 15 November 2022
- journal article
- research article
- Published by Academic World Research in Medical Journal of the Islamic Republic Of Iran
- Vol. 36 (1) , 1020-1029
Abstract
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel severe acute respiratory syndrome coronavirus. The first known receptor for this virus in the human body is angiotensin-converting enzyme 2 (ACE2), the same receptor for the SARS virus. Methods: A total of 38 hospitalized adult (18 years) patients with laboratory or ...Keywords
All Related Versions
This publication has 21 references indexed in Scilit:
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?Clinical Science, 2020
- IKKβ overexpression together with a lack of tumour suppressor genes causes ameloblastic odontomas in miceInternational Journal of Oral Science, 2020
- Altered Renal Expression of Angiotensin II Receptors, Renin Receptor, and ACE-2 Precede the Development of Renal Fibrosis in Aging RatsAmerican Journal of Nephrology, 2010
- Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2Hypertension, 2010
- Expression of ACE and ACE2 in Individuals With Diabetic Kidney Disease and Healthy ControlsAmerican Journal of Kidney Diseases, 2008
- Chloroquine is a potent inhibitor of SARS coronavirus infection and spreadVirology Journal, 2005
- Myocardial infarction increases ACE2 expression in rat and humansEuropean Heart Journal, 2005
- The involvement of survival signaling pathways in rubella-virus induced apoptosisVirology Journal, 2005
- Renal ACE2 expression in human kidney diseaseThe Journal of Pathology, 2004